| Classification | n | % |
| Total | 1373 | 100% |
| Screening group† | 590 | 43% |
| TST negative | 337 | 57.1% |
| TST, positive: No LTBI | 207 | 35.1% |
| TST under 15 mm | 143 | 69.1% |
| TST ≥ 15 mm | 64 | 30.9% |
| TST, positive: LTBI | 46 | 7.8% |
| IPT completed | 31 | 67.4% |
| Other (LTFU, IPT discontinued, etc.) | 15 | 32.6% |
| Contact tracing group† | 649 | 47.3% |
| TST negative | 33 | 5.1% |
| TST, positive: No LTBI | 264 | 40.7% |
| TST under 15 mm | 171 | 64.8% |
| TST ≥ 15 mm | 93 | 35.2% |
| TST, positive: LTBI | 352 | 54.2% |
| IPT completed | 228 | 64.8% |
| Other (LTFU, IPT discontinued, etc.) | 124 | 35.2% |
| Medical condition group† | 134 | 9.8% |
| TST negative | 38 | 28.4% |
| TST, positive: No LTBI | 58 | 43.3% |
| TST under 15 mm | 41 | 70.7% |
| TST ≥ 15 mm | 17 | 29.3% |
| TST, positive: LTBI | 38 | 28.4% |
| IPT completed | 25 | 65.8% |
| Other (LTFU, IPT discontinued, etc.) | 11 | 28.9% |